• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PPBT

    Purple Biotech Ltd.

    Subscribe to $PPBT
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. Its oncology pipeline includes NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. was founded in 2010 and is headquartered in Rehovot, Israel.

    IPO Year: 2015

    Exchange: NASDAQ

    Website: purple-biotech.com

    Recent Analyst Ratings for Purple Biotech Ltd.

    DatePrice TargetRatingAnalyst
    See more ratings

    Purple Biotech Ltd. SEC Filings

    View All

    SEC Form 6-K filed by Purple Biotech Ltd.

    6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

    9/5/25 12:43:24 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B4 filed by Purple Biotech Ltd.

    424B4 - PURPLE BIOTECH LTD. (0001614744) (Filer)

    9/5/25 8:30:31 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Purple Biotech Ltd.

    EFFECT - PURPLE BIOTECH LTD. (0001614744) (Filer)

    9/5/25 12:15:27 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Purple Biotech Ltd.

    6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

    9/4/25 7:03:02 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Purple Biotech Ltd.

    6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

    9/3/25 7:10:27 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form F-1 filed by Purple Biotech Ltd.

    F-1 - PURPLE BIOTECH LTD. (0001614744) (Filer)

    8/29/25 9:14:20 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Purple Biotech Ltd.

    6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

    8/6/25 7:02:48 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Purple Biotech Ltd.

    6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

    7/23/25 7:02:26 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Purple Biotech Ltd.

    6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

    7/10/25 4:11:17 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Purple Biotech Ltd.

    6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

    6/23/25 7:06:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Ltd. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

    REHOVOT, Israel, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced public offering of an aggregate of 5,999,999 of the Company's American Depositary Shares (ADSs) (or pre-funded warrants in lieu thereof), with each ADS representing 200 ordinary shares, and short-term warrants to purchase up to 11,999,998 ADSs, at a combined public offering price of $1.00 per share (or pre-funded warrant in lieu thereof) and accompanying short-term warrants. The short

    9/5/25 4:00:00 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Announces Pricing of Up To $18 Million Public Offering

    $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants REHOVOT, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the pricing of a public offering of an aggregate of 5,999,999 of the Company's American Depositary Shares (ADSs) (or pre-funded warrants in lieu thereof), with each ADS representing 200 ordinary shares, and short-term warrants to purchase up to 11,999,998 ADSs, at a combined public

    9/4/25 9:15:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai

    Mt. Sinai Principal Investigator, Dr. Amir Horowitz, demonstrates tumor cell death induced by IM1240 in patient-derived treatment-resistant head and neck biopsies Synergistic effects were observed between the NK and the T cell engager arms of IM1240, a unique combination in the CAPTN-3 platform Analysis of approximately 26,000 human transcriptomes suggests that NKG2A expression is consistently accompanied by 5T4 in solid tissues, but not in blood, supporting the design of IM1240 IM1240, the first CAPTN-3 tri-specific antibody targeting 5T4, a novel tumor-associated antigen, advances toward first-in-human clinical trials, with IND submission planned for 2026 REHOVOT, Israel, Sept. 04, 2

    9/4/25 7:00:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2

    Encouraging in-vivo results demonstrate sustained tumor regression with the CD3xTROP2xNKG2A antibody First CAPTN-3 tri-specific antibody, IM1240, targeting the novel tumor associated antigen 5T4 advances toward first-in-human clinical trials, with Investigational New Drug (IND) submission planned for 2026 REHOVOT, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced its second CAPTN-3 trispecific antibody, targeting TROP2 in development.  Purple Biotech has advanced development of

    9/3/25 7:00:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

    REHOVOT, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that the Company's CEO, Gil Efron will participate in a fireside chat and 1x1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025. Details are as follows: H.C. Wainwright 27th Annual Global Investment Conference Format: Fireside Chat Date: Wednesday, September 10, 2025Time: 11:30 AM ET Management will be holding 1 x 1 meetings as well. Please schedule throu

    8/27/25 7:00:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Reports Second Quarter 2025 Financial Results

    Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform's masked CD3, NKG2A, and tumor-associated antigen arms First CAPTN-3 trispecific antibody targeting novel tumor associated antigen, 5T4, advances toward first-in-human clinical trials, with IND submission expected in 2026 Positive Phase 2 data from CM24 study in biomarker-enriched pancreatic ductal adenocarcinoma (PDAC) reported at AACR 2025 NT219 Phase 2 study in head and neck cancer initiated in June 2025 REHOVOT, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-st

    8/6/25 7:00:58 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

    REHOVOT, Israel, July 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today issued the following letter to shareholders from Chief Executive Officer Gil Efron, highlighting the Company's scientific progress, operational execution, and strategic milestones during the first half of 2025. Dear Shareholders, I am pleased to report that the first half of 2025 has been marked by meaningful scientific advancements across all of our core programs, prudent financial management, and continued investor support. Despite

    7/23/25 7:00:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

    REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the presentation of new preclinical data on its novel CAPTN-3 tri-specific antibody platform in a poster presentation at the 2025 Annual Congress of the European Association for Cancer Research (EACR 2025), that was held in Lisbon, Portugal from June 16-19, 2025. "Purple's proprietary CAPTN-3 platform of T-cell engagers enables the creation of a large number of antibodies to different targets, and by capping the anti-CD3 a

    6/23/25 7:00:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer

    Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in combination with either pembrolizumab or cetuximab as a strategy to overcome tumor resistance REHOVOT, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the initiation of a Phase 2 clinical study evaluating NT219 in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). NT219 is a novel small molecule designed to target

    6/17/25 7:00:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform

    REHOVOT, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced a poster presentation on its novel CAPTN-3 tri-specific antibody platform, will be featured at the Annual Congress of the European Association for Cancer Research (EACR) 2025, being held in Lisbon, Portugal from June 16 – 19, 2025. EACR poster details are as follows: Abstract #: EACR25-1964Title: "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers"Session Title: ImmunotherapySession Date and T

    6/4/25 7:00:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Ltd. Financials

    Live finance-specific insights

    View All

    Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

    Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the year and the three months ended December 31, 2022. "We are reporting our 2022 financial results which are in line with our plans," said Gil Efron, Chief Executive Officer of Purple Biotech. "Our end-of-y

    2/8/23 7:12:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Ltd. Leadership Updates

    Live Leadership Updates

    View All

    Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

    REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the presentation of new preclinical data on its novel CAPTN-3 tri-specific antibody platform in a poster presentation at the 2025 Annual Congress of the European Association for Cancer Research (EACR 2025), that was held in Lisbon, Portugal from June 16-19, 2025. "Purple's proprietary CAPTN-3 platform of T-cell engagers enables the creation of a large number of antibodies to different targets, and by capping the anti-CD3 a

    6/23/25 7:00:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Reports First Quarter 2025 Financial Results

    Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025 NT219 data presented at AACR Annual Meeting 2025; NT219 Phase 2 study in head and neck cancer on track to be initiated in First Half of 2025 CAPTN-3 differentiated T-cells and NK cells engagers tri-specific platform advances toward first-in-human clinical trials REHOVOT, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, annou

    5/21/25 7:10:40 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

    Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company's Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Dr. Yael Margolin as an independent member of the Company's Board of Directors. Dr. Yael Margolin has more than 35 years of experience as senior manager, c

    12/20/23 8:05:00 AM ET
    $GMDA
    $PNT
    $PPBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

    Board of Directors appoints Isaac Israel, Board member and former CEO, as acting CEOCompany's business plan and clinical development programs continue as planned REHOVOT, Israel, March 24, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment (TME) to overcome tumor immune evasion and drug resistance, today announced that the CEO, Gil Efron, has been hospitalized following an accident and will be on medical leave that is expected to last several months while he undergoes rehabilitation to recover from h

    3/24/23 7:00:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Appoints Lior Fhima as Chief Financial Officer

    Seasoned financial executive strengthens management team  REHOVOT, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Lior Fhima, CPA, MBA, as Chief Financial Officer of the Company.  Mr. Fhima brings deep expertise in financial management in the pharmaceutical industry and strong managerial capabilities. "We are honored to welcome Lior Fhima to the executive management team," said Gil Efron, Ch

    11/2/22 7:37:26 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors

    REHOVOT, Israel, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Ori Hershkovitz, a long-time life sciences industry investor, to its Board of Directors. "We are thrilled to welcome Ori to the Purple Biotech Board of Directors," said Dr. Eric Rowinsky, Chairman of the Board of Purple Biotech. "Ori has spent many years investing in and advising development-stage life sciences companies.   We look forward to leveraging his industry and finan

    1/6/22 7:30:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer

    REHOVOT, Israel, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Fabien Sebille, Ph.D., a senior business development executive with more than 15 years of professional experience in the biotechnology industry, as its Chief Business Officer. Dr. Sebille, who has led a series of licensing deals in oncology over the last four years, will be primarily responsible for business development, including strategic partnering opportunities. Previously, Dr. Sebil

    12/9/21 7:30:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors

    REHOVOT, Israel, May 19, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Suzana Nahum-Zilberberg, a seasoned biopharmaceutical Industry executive, to its Board of Directors. "We are excited to welcome Suzana to our Board of Directors," said Dr. Eric Rowinsky, Chairman of the Board of Purple Biotech. "Ms. Nahum-Zilberberg has extensive experience in senior leadership positions at several leading biopharmaceutical companies.  As we continue to expeditiously adva

    5/19/21 7:00:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Ltd. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Purple Biotech Ltd.

    SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)

    11/14/24 5:21:29 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Purple Biotech Ltd.

    SC 13G - PURPLE BIOTECH LTD. (0001614744) (Subject)

    2/14/24 3:49:16 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Purple Biotech Ltd. (Amendment)

    SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)

    4/9/21 4:34:41 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)

    2/16/21 10:04:35 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)

    2/5/21 10:12:31 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed

    SC 13G - PURPLE BIOTECH LTD. (0001614744) (Subject)

    2/4/21 4:29:30 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care